Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
95.01
+2.25 (2.43%)
At close: Oct 9, 2026, 4:00 PM EDT
95.11
+0.10 (0.11%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Inhibrx Biosciences Revenue
In the year 2025, Inhibrx Biosciences had annual revenue of $1.30M with 550.00% growth. That makes Inhibrx Biosciences the 43,146th largest company in the world by revenue and 5,968th in the United States.
Revenue (ttm)
$1.30M
Revenue Growth
+550.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
110
Market Cap
1.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.30M | 1.10M | 550.00% |
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AnaptysBio | 106.09M |
| Ascentage Pharma Group International | 94.61M |
| Nektar Therapeutics | 54.59M |
| Omeros | 38.42M |
| Taysha Gene Therapies | 5.49M |
INBX News
- 16 days ago - Inhibrx director buys $500K in common stock - TheFly
- 4 weeks ago - Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study - Reuters
- 4 weeks ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 4 weeks ago - Inhibrx Biosciences Press release: Study update - Filings
- 4 weeks ago - Inhibrx Biosciences Slides: Study update - Filings
- 4 weeks ago - Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study - TheFly
- 4 weeks ago - Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study - PRNewsWire
- 5 weeks ago - Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study - PRNewsWire